News
-
03 October 2013
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine
NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that it has closed a $14M Series B financing.
-
01 October 2013
Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced positive results from its Phase 2b RESET clinical study of LIPO-202 (Salmeterol Xinafoate for Injection).
-
30 September 2013
Syndax scores a coveted 'breakthrough' designation for PhIII cancer drug
Syndax Pharmaceuticals has scored a rare win for a small, private biotech, snagging the FDA's breakthrough designation for a Phase III-ready breast cancer therapy just days after rolling up a $27 million venture round.
-
26 September 2013
NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine
NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the initiation of a Phase 1b/2a clinical trial to evaluate its NDV-3 vaccine in preventing episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC).
-
23 September 2013
Garrett Johnston: Russian capital, brands, ideas and people can and must change the whole world for the better.
-
17 September 2013
Regado Biosciences, Inc. enrolls first patient in phase 3 trial of REG1
Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.
-
11 September 2013
Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration(FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.
-
05 September 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers and Eddingpharm, a leading specialty pharmaceutical company in China, entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market and sell entinostat in China and certain other Asian countries/regions.
-
29 August 2013
Tragara Completes $12M Series B Financing New Round to Fund Continued Clinical Development of TG02
Tragara Pharmaceuticals, Inc. announced today that it has secured $12 million in the close of a Series B financing. Participating investors included Domain Associates, Mitsubishi International Corporation, Morganthaler Ventures, ProQuest Investments and RusnanoMedInvest (RMI).
-
27 August 2013
Syndax Pharmaceuticals Inc., which is developing epigenetic therapies for treatment-resistant cancers, today announced it has secured a $26.6 million Series B financing.